Login
Israel-Hamas Conflict
Motorsports
Social Media
Natural Disasters
Floods
World Cup
Artificial Intelligence
Education
BRICS
Independence Day
Wrestling
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

ILCN.org (ILCN/WCLC) image

News from ILCN.org (ILCN/WCLC)

If you want to know if ILCN.org (ILCN/WCLC) is credible or reliable, look no further. We rank ILCN.org (ILCN/WCLC) as Unknown factuality. Find out more about our methodology here.

Information about ILCN.org (ILCN/WCLC)

Where is ILCN.org (ILCN/WCLC) located?ILCN.org (ILCN/WCLC)'s Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ILCN.org (ILCN/WCLC) News

MHRA Approves Serplulimab for Extensive-Stage SCLC
FDA · United States

MHRA Approves Serplulimab for Extensive-Stage SCLC

67% Center coverage: 3 sources
The MHRA has approved serplulimab, the UK’s first anti-PD-1 antibody for extensive-stage small cell lung cancer, improving survival options for adults.See the Story
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC - ILCN.org (ILCN/WCLC)
Maryland · Maryland

A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC - ILCN.org (ILCN/WCLC)

The CheckMate 816 trial, which evaluated neoadjuvant nivolumab in combination with chemotherapy, demonstrated a significant survival advantage versus chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC). Patrick Forde, MD Additionally, data confirmed a durable event-free survival (EFS) benefit. Patrick M. Forde, MD, PhD, Trinity St. James’s Cancer Institute, Trinity College Dublin, presented the latest and final ove…Read Article
Patient Perspective: Copay Accumulators Create Yet Another Cost Burden Faced by US Patients in Treatment with Targeted Therapies - ILCN.org (ILCN/WCLC)
United States · United States

Patient Perspective: Copay Accumulators Create Yet Another Cost Burden Faced by US Patients in Treatment with Targeted Therapies - ILCN.org (ILCN/WCLC)

Adding to the Kafkaesque financial toxicities that can accompany long-term treatment—I’m required by the internationally recognized rules of patient engagement to invoke an allusion to Kafka—is an insurance scheme that is short on transparency, shifts the burden of cost to the patient, and which has become a widespread practice in the United States: copay accumulators and maximizers. Annabelle Gurwitch As Monica Bryant, COO of Triage Cancer put…Read Article

Research to Watch: FDA Grants ZL-1310 Fast Track Designation for Extensive-Stage SCLC - ILCN.org (ILCN/WCLC)

The US Food and Drug Administration (FDA) has granted Fast Track Designation to ZL-1310 for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This decision underscores the ongoing need to develop new therapies for patients with small cell lung cancer (SCLC) and marks an important step forward in clinical progress. The designation is based on updated results from an ongoing phase 1a/1b trial, which were presented at the 2025 Amer…Research · United StatesRead Article

Rethinking Radiation: Adopting Hypofractionated Radiation Therapy - ILCN.org (ILCN/WCLC)

Puneeth Iyengar, MD, PhD, and Edward Christopher Dee, MD, recently discussed the environmental costs of cancer treatment in an interview with ILCN. In part two of our series, Dr. Iyengar, a radiation oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), New York, and Dr. Dee, a third-year resident at MSKCC, explore the benefits and challenges of adopting hypofractionated radiation schedules. Puneeth Iyengar, MD, PhD ILCN: What is hypofr…Maryland · MarylandRead Article

Global Insights into Smoking Cessation in Lung Cancer Screening - ILCN.org (ILCN/WCLC)

Rachael Murray, PhD, MS, BSc Smoking cessation interventions are a critical component of lung cancer screening (LCS) programs, as they have been shown to reduce smoking-related risks and improve screening outcomes. Evidence increasingly supports the inclusion of high-intensity and opt-out smoking cessation services at the point of screening as having the greatest impact. Despite this, the implementation of cessation support within LCS programs v…United States · United StatesRead Article

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC

Coverage: 2 sources
The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.Medical · United StatesSee the Story

Gene Assay May Guide Chemo Use in Early NSCLC: ASCO 2025

A 14-gene molecular assay may help identify early-stage non-squamous NSCLC patients who benefit from chemotherapy post-surgery, potentially guiding adjuvant treatment decisions.See the Story

Overcoming Resistance Remains a Challenge in Targeting KRAS - ILCN.org (ILCN/WCLC)

Alice Shaw, MD, PhD For several decades, RAS has been considered a potent oncogenic driver; however, until the development of KRAS G12C inhibitors, it was deemed “undruggable.” “This early success with G12C inhibitors, along with additional key insights into targeting RAS, has fueled this explosion and drug discovery, with numerous new RAS inhibitors now in preclinical and clinical development,” said Alice Shaw, MD, PhD, on April 28 during a ses…Maryland · MarylandRead Article

Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does? - ILCN.org (ILCN/WCLC)

Immune checkpoint inhibitors (ICIs) are largely considered a game-changer for patients with non-small cell lung cancer (NSCLC), delivering survival benefits in both early and advanced stages of the disease. However, between 3% and 12% of patients treated with a single ICI, and up to 25% of patients treated with immunotherapy combinations, must discontinue treatment due to immune-related adverse events (irAEs). Mark Awad, MD, PhD “When immunothe…Maryland · MarylandRead Article

Falling Through the Cracks: Battling Barriers in Lung Cancer Care - ILCN.org (ILCN/WCLC)

Inspired by both the call to help people during their worst days and the excitement of the role, Daiyo Ito decided to make a major career shift nearly 7 years ago from a branch manager at a rental car agency to a firefighter with the Pasadena Fire Department. Since then, Mr. Ito has responded to wildfire outbreaks across California, but things were different in January 2025 when the Los Angeles County Wildfires erupted across the region. Mr. Ito…Maryland · MarylandRead Article

Breaking News Topics Related to ILCN.org (ILCN/WCLC)

Maryland icon

Maryland

FDA icon

FDA

United States icon

United States

Texas, United States icon

Texas, United States

Cancer icon

Cancer

News
For You
SearchBlindspotLocal